CL2019003498A1 - Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores. (divisional solicitud 201802828) - Google Patents

Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores. (divisional solicitud 201802828)

Info

Publication number
CL2019003498A1
CL2019003498A1 CL2019003498A CL2019003498A CL2019003498A1 CL 2019003498 A1 CL2019003498 A1 CL 2019003498A1 CL 2019003498 A CL2019003498 A CL 2019003498A CL 2019003498 A CL2019003498 A CL 2019003498A CL 2019003498 A1 CL2019003498 A1 CL 2019003498A1
Authority
CL
Chile
Prior art keywords
reduction
tumor
gamma
receptor
antibodies against
Prior art date
Application number
CL2019003498A
Other languages
English (en)
Inventor
Sergio Quezada
Karl Peggs
Fred Vargas
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of CL2019003498A1 publication Critical patent/CL2019003498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN HACE REFERENCIA A UN MÉTODO PARA EL TRATAMIENTO DE UN TUMOR SÓLIDO, DONDE DICHO MÉTODO IMPLICA EL USO DE UN ANTICUERPO CONTRA CD25. EN PARTICULAR, EL ANTICUERPO CONTRA CD25 SE OPTIMIZA PARA LA REDUCCIÓN DE LINFOCITOS T REGULADORES (TREG) DENTRO DE TUMORES. SE PROPORCIONA TAMBIÉN ANTICUERPOS ANTI-CD25 NOVEDOSOS Y SU COMBINACIÓN CON OTROS FÁRMACOS CONTRA EL CÁNCER, TALES COMO INHIBIDORES DE PUNTOS DE CONTROL DEL SISTEMA INMUNITARIO, COMPUESTOS QUE SE DIRIGEN A ANTÍGENOS CONTRA EL CÁNCER O EL RECEPTOR DE FC INHIBIDOR FCYRIIB (CD32B).
CL2019003498A 2016-04-07 2019-11-29 Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores. (divisional solicitud 201802828) CL2019003498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201605947 2016-04-07

Publications (1)

Publication Number Publication Date
CL2019003498A1 true CL2019003498A1 (es) 2020-05-29

Family

ID=58358618

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018002828A CL2018002828A1 (es) 2016-04-07 2018-10-04 Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores.
CL2019003498A CL2019003498A1 (es) 2016-04-07 2019-11-29 Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores. (divisional solicitud 201802828)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018002828A CL2018002828A1 (es) 2016-04-07 2018-10-04 Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores.

Country Status (13)

Country Link
US (2) US20190135925A1 (es)
EP (1) EP3440109A1 (es)
JP (1) JP7325959B2 (es)
KR (2) KR20220032642A (es)
CN (1) CN109476739A (es)
AU (1) AU2017247880B2 (es)
BR (1) BR112018070636A2 (es)
CA (1) CA3020204A1 (es)
CL (2) CL2018002828A1 (es)
IL (1) IL262129A (es)
MX (1) MX2018012319A (es)
RU (1) RU2759970C2 (es)
WO (1) WO2017174331A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
CN109476739A (zh) 2016-04-07 2019-03-15 癌症研究技术有限公司 用于肿瘤特异性细胞消减的抗CD25 FCγ受体双特异性抗体
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
GB201712032D0 (en) 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof
US20200362036A1 (en) * 2018-01-10 2020-11-19 Bioinvent International Ab Novel combination and use of antibodies
EP3765502B1 (en) * 2018-03-13 2024-08-07 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
EP3566718A1 (en) * 2018-05-07 2019-11-13 Universitätsmedizin der Johannes Gutenberg-Universität Mainz A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer
US20220213225A1 (en) * 2018-07-30 2022-07-07 Invenra Inc. Multispecific treg binding molecules
CN113272330B (zh) * 2019-03-02 2024-07-26 南通壹宸生物医药科技有限公司 一种双特异抗体
WO2021145946A1 (en) * 2020-01-13 2021-07-22 Invenra Inc. Multispecific treg binding molecules
US20230192900A1 (en) * 2020-02-13 2023-06-22 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
WO2021228218A1 (zh) 2020-05-14 2021-11-18 江苏恒瑞医药股份有限公司 抗cd25抗体、其抗原结合片段及其医药用途
KR20230107641A (ko) * 2020-11-13 2023-07-17 아이바이오, 인크. Cd25 항체
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
EP4396230A1 (en) 2021-09-02 2024-07-10 F. Hoffmann-La Roche AG Antibodies for the treatment of aml
TW202336033A (zh) * 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途
WO2023208990A1 (en) 2022-04-26 2023-11-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist,
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2024151091A1 (ko) * 2023-01-11 2024-07-18 한국과학기술원 종양 내 treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물
WO2024165454A1 (en) 2023-02-06 2024-08-15 F. Hoffmann-La Roche Ag Combination therapy and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578397B1 (en) * 2002-11-15 2012-12-26 Genmab A/S Human monoclonal antibodies against cd25
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
US8586023B2 (en) * 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
EP2970486B1 (en) * 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CN109476739A (zh) 2016-04-07 2019-03-15 癌症研究技术有限公司 用于肿瘤特异性细胞消减的抗CD25 FCγ受体双特异性抗体

Also Published As

Publication number Publication date
KR20190017735A (ko) 2019-02-20
RU2759970C2 (ru) 2021-11-19
MX2018012319A (es) 2019-06-06
CN109476739A (zh) 2019-03-15
JP7325959B2 (ja) 2023-08-15
KR20220032642A (ko) 2022-03-15
CA3020204A1 (en) 2017-10-12
EP3440109A1 (en) 2019-02-13
RU2018135247A3 (es) 2021-01-20
US20230265200A1 (en) 2023-08-24
AU2017247880A1 (en) 2018-11-15
AU2017247880B2 (en) 2024-07-11
BR112018070636A2 (pt) 2019-02-05
US20190135925A1 (en) 2019-05-09
RU2018135247A (ru) 2020-05-12
WO2017174331A1 (en) 2017-10-12
IL262129A (en) 2018-11-29
JP2019513725A (ja) 2019-05-30
CL2018002828A1 (es) 2019-03-08

Similar Documents

Publication Publication Date Title
CL2019003498A1 (es) Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores. (divisional solicitud 201802828)
CR20190477A (es) Versión optimizada para fc de anticuerpo anti-cd25 para la reducción celular específica de tumor
AU2017228470A8 (en) Combination therapy with anti-CD73 antibodies
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
CL2017001328A1 (es) Anticuerpos heterodimericos que unen cd3 y antígenos tumorales
CR20200466A (es) Agentes anticuerpos anti-cd25
PE20210256A1 (es) Anticuerpos anti-lag3
BR112019002687A2 (pt) receptores de antígeno quimérico que direcionam bcma e métodos de uso dos mesmos
MY192822A (en) An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
BR112017008710A8 (pt) Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
AR117685A1 (es) Antígeno quimérico y receptores de células t y métodos de uso
RU2017134104A (ru) Композиции и способы повышения эффективности противораковой терапии
CO2021010347A2 (es) Células modificadas por receptor de antígeno quimérico para el tratamiento de cánceres que expresan cldn6
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
CO2022004603A2 (es) Inmunoterapia con anticuerpos biespecíficos de células car
MX2022005816A (es) Terapia de tumores solidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70.
BR112021021542A2 (pt) Terapia celular alogênica de malignidades de células b com o uso de células t geneticamente modificadas que têm como alvo cd19
WO2019070161A3 (en) Articles and methods directed to personalized therapy of cancer
BR112022010345A2 (pt) Tratamento envolvendo células efectoras imune projetadas por receptores de antígeno
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células
PH12020551453A1 (en) Anti-cd25 for tumour specific cell depletion
MX2022002363A (es) Sistema receptor de antígeno quimérico y usos de este.
WO2020081579A8 (en) Monoclonal antibodies against human dickkopf3 and uses thereof
Intisar et al. Adoptive T-cell immunotherapy using chimeric antigen receptor against a novel cancer target Axl